MHESI, Mahidol, Betagro and NZeno Launch T-Xeno Hub to Tackle Thailand's Donor Organ Shortage

Group photo of the MU BioGro partnership announcement at Prince Mahidol Hall

The Ministry of Higher Education, Science, Research and Innovation (MHESI) and Mahidol University have forged a historic collaboration with Betagro and NZeno Limited (New Zealand). The partnership marks a significant breakthrough in Advanced Medicine concerning Xenotransplantation (animal-to-human organ transplantation). The initiative highlights the research and development of genetically modified pigs raised in Designated Pathogen-Free (DPF) environments, targeting successful "pig kidney" transplantations to resolve the critical shortage of donor organs and improve patient survival rates. Furthermore, the partners announced the establishment of MU BioGro Co., Ltd. to drive the T-Xeno Hub project, positioning Thailand as the first xenotransplantation center in ASEAN and opening the door to a sustainable global Wellness Economy.

Prof. Dr. Yodchanan Wongsawat, Deputy Prime Minister and Minister of Higher Education, Science, Research and Innovation (MHESI), stated that health security is the foundation of a nation's economy, as it helps reduce the government's budgetary burden and enhances the country's competitiveness. Developing advanced medical innovations is not solely an economic endeavor, but a vital national agenda to save Thai lives, elevate the quality of life, and ensure equitable access to medical treatment, with universities acting as the primary driving force. Therefore, MHESI aims to elevate the role of Thai universities beyond merely producing graduates. They must evolve into "Mastery Platforms," serving as the core of a Mastery Ecosystem that bridges advanced science with deep technology (Deep Tech). Ultimately, this will transition Thailand from a technology buyer to a country capable of researching, developing, and creating its own advanced innovations in the long term.

Speaker on stage in front of an AI for Thai Discovery slide

Prof. Dr. Yodchanan added that Mahidol University's collaboration on xenotransplantation technology represents a strategic milestone that tangibly responds to MHESI's Flagship policy. This aligns particularly with the "SIAM MEDICA" pillar, which focuses on building excellence and advanced mastery in Medicine & Scientific Wellness, Medical Devices, and Advanced Therapy Medicinal Products (ATMP). Driving the T-Xeno Hub project reflects a powerful synergy among higher education institutions, the industrial sector, and global partners. By utilizing Deep Tech and innovation to propel the Wellness Economy, this initiative fosters steady growth and paves the way for novel treatments that will restore hope and increase the survival chances of Thai patients in the future.

Prof. Piyamitr Sritara, FRCP, President of Mahidol University, noted that developing research for societal benefit is a critical strategic direction for the university. Under the "Real World Impact" vision, the university strives to translate academic knowledge and expertise into practical outcomes that solve real-world problems. This is especially true for advancing medical knowledge and technology to increase public access to treatment. One of the major challenges in the Thai public health system is the severe shortage of organs for transplantation. Thailand currently has over 110,000 patients with chronic kidney disease. Data from 2024 indicated that while approximately 23,000 patients met the criteria for a kidney transplant, only 989 actually received one. Consequently, patients waiting for a transplant may face wait times exceeding 5 years, and many tragically pass away before receiving an organ. Beyond the impact on patients' lives, treatments requiring renal replacement therapy place a heavy financial burden on the public health system, costing the National Health Security system approximately 36,678 million baht annually. This situation underscores the urgent need to develop advanced medical knowledge and technology to expand treatment options, overcome organ availability constraints, and bolster Thailand's long-term capacity to manage health challenges.

Speaker holding a microphone on stage

"One globally recognized approach is Xenotransplantation, or cross-species organ transplantation," Prof. Piyamitr explained. "This involves studying the use of animal organs, particularly from genetically modified pigs, for human transplantation, as pigs share suitable organ sizes and certain physiological characteristics with humans. However, this technology requires comprehensive research and rigorous safety evaluations. Therefore, Mahidol University—led by the Faculty of Medicine Ramathibodi Hospital, in collaboration with the Faculty of Veterinary Science and the Faculty of Medicine Siriraj Hospital—is advancing the Thailand Xenotransplantation Hub, or T-Xeno Hub. This initiative aims to lay the groundwork for xenotransplantation research in Thailand by developing a Designated Pathogen-Free (DPF) genetically modified pig research platform, building upon animal cloning technology, genetic design, and biosecurity control. We have outlined an initial 18-month operational plan to elevate our Technology Readiness Level from TRL 4 to TRL 5, alongside facilitating knowledge transfer from international experts to develop personnel and strengthen Thailand's research capacity in advanced medical technology."

Prof. Piyamitr further noted that the readiness to drive this initiative stems from Mahidol University's unique strengths. The Faculty of Veterinary Science, ranked 63rd globally, brings over 16 years of extensive expertise in animal cloning. This expertise is synergized with the two medical schools—the Faculty of Medicine Ramathibodi Hospital and the Faculty of Medicine Siriraj Hospital—both of which hold top-tier national experience and continuous expertise in kidney transplantation and patient care for kidney disease. However, transitioning this advanced research from the laboratory to safe, practical application requires the Triple Helix model of collaboration between the government, academic institutions, and the industrial sector to tangibly advance the T-Xeno Hub. Mahidol University has partnered with Betagro Public Company Limited to merge the university's research capabilities with the private sector's manufacturing potential and infrastructure. This collaboration supports the development of a Designated Pathogen-Free (DPF) pig production system and includes the establishment of MU BioGro Co., Ltd. This company will act as the crucial mechanism linking research to industry, covering everything from technology and production process development to the creation of commercial medical innovations. Additionally, a partnership with NZeno Limited from New Zealand will strengthen the technology and specialized knowledge required for xenotransplantation development. By bringing in international expertise to support the development of genetically modified pig technology and related research processes, as well as transferring knowledge and upskilling Thai research teams, this collaboration lays the foundation for future human xenotransplantation clinical trials under strict safety guidelines.

Speaker on stage in front of the T-Xeno Hub project slide

"The Triple Helix collaboration among the government, academic institutions, and industrial sectors—both domestic and international—to drive the T-Xeno Hub will serve as a crucial foundation for developing xenotransplantation technology in Thailand. It will provide an alternative source of organs, increase survival chances, and improve patients' quality of life, while reducing the long-term financial burden on the public healthcare system. This reflects Mahidol University's unwavering commitment to developing research for the benefit of society," Prof. Piyamitr added.

Mr. Vasit Taepaisitphongse, Chief Executive Officer and President of Betagro Public Company Limited, stated that the development of Xenotransplantation is a prime example of leveraging industrial expertise to advance medical technology. This aligns with Betagro's vision of expanding its role from ensuring Food Security to fostering Sustainable Life, utilizing its capabilities and knowledge in the livestock industry to support research that generates meaningful societal benefits. Betagro recognizes the importance of developing standardized infrastructure and production systems, which are essential factors for systematically advancing xenotransplantation technology research.

Speaker on stage in front of a 59 Years of Trusted Leadership slide

"With over 59 years of experience in the integrated agro-industrial and food sector, Betagro is ready to bring our expertise in farm management, Specific Pathogen-Free (SPF) livestock systems, and biosecurity quality control systems to support the development of Designated Pathogen-Free (DPF) pig production systems. We are undertaking this in collaboration with Mahidol University and our technology partners. A key component of this partnership is the development of a medical-grade DPF pig production center at Mahidol University, Kanchanaburi Campus, which is expected to be completed within 18 months. This facility will house pigs under controlled environments and rigorous biosecurity standards suitable for research, requiring systematic environmental management, quality control, and pathogen surveillance for the subsequent phases of xenotransplantation technology development. This collaboration strongly reflects the private sector's role in co-investing and building new capabilities for the country. We are not just supporting early-stage research; we are laying the foundation for continuous advanced medical technology development and expanding future treatment options for Thai patients to ensure widespread and equitable access," Mr. Vasit concluded.

Mr. Peter Lai, Chief Executive Officer of NZeno Limited (New Zealand), noted that NZeno is a biotechnology company specializing in developing pigs for xenotransplantation. The company has deep expertise in porcine cell gene editing, the development of genetically modified pigs, and Designated Pathogen-Free (DPF) pig rearing systems aimed at creating viable organ sources for human transplantation. NZeno has extensive experience operating DPF pig systems in New Zealand and maintains active technological partnerships internationally. This serves as a vital foundation for contributing specialized knowledge to support the development of the T-Xeno Hub. A critical component in xenotransplantation development is preparing high-quality, medical-grade cell lines. NZeno will play a key role in technology transfer and supplying these cells, which will serve as the starting point for developing genetically modified pigs for cross-species transplantation research. Furthermore, NZeno will transfer knowledge on pig development and biosecurity control standards, particularly for DPF farming, which requires rigorous and systematic pathogen surveillance. This is essential to minimize infection risks associated with utilizing porcine cells, tissues, or organs in humans.

"NZeno is confident that this collaboration with Mahidol University and our Thai partners presents a crucial opportunity to expand knowledge and technology within Thailand. Our goal is not merely to transfer technology from abroad, but to jointly build expertise and research capabilities. This will establish a robust foundation, enabling Thailand to systematically develop Xenotransplantation technology through rigorous research and the highest safety evaluations," Mr. Lai concluded.

ลงทะเบียนเข้าสู่ระบบ เพื่ออ่านบทความฟรีไม่จำกัด

No comment

RELATED ARTICLE

Responsive image

In Conversation with Eric Tse, Heir to One of China's Leading Pharmaceutical Groups, on Lessons from SBP Group's 20-Year Path to Global Success

Techsauce had the opportunity to speak with Eric Tse, the son of Tse Ping, who has fully taken over as Chairman of CTTQ and CEO of SBP Group....

Responsive image

Disrupt Health Impact Fund Invests in US-based Osteoboost First-and-only FDA-cleared wearable to slow bone density loss

Disrupt Health Impact Fund backs US startup Osteoboost, tapping into the booming Women's HealthTech market. Read how this deal shapes the future of Silver Age tech....

Responsive image

Mahidol Launches 15-Minute Melioidosis Rapid Test with 95% Accuracy, Aiming to Tackle Thailand’s Rising "Soil Fever" Threat

A research team from Mahidol University has developed the MUTM Melioidosis Antibody Test. This innovative rapid test kit delivers results within 15 minutes with over 95% accuracy....